HCV in injecting drug users: developing indicators of prevalence and responses
Polymorphisims why individual drug responses vary
-
Upload
ashwin1609 -
Category
Health & Medicine
-
view
326 -
download
0
Transcript of Polymorphisims why individual drug responses vary
![Page 1: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/1.jpg)
POLYMORPHISIMS: WHY INDIVIDUAL DRUG RESPONSES VARY
S.Ashwin kumar Mims
Vizianagaram, AP
![Page 2: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/2.jpg)
Single nucleotide polymorphisms (SNPs)
• SNPs are single base pair positions in genomic DNA at which different sequence alternatives (alleles) exist wherein the least frequent allele has an abundance of 1% or greater.
• SNPs are the most commonly occurring genetic differences.
![Page 3: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/3.jpg)
• SNPs are very common in the human population.
• Between any two people, there is an average of one SNP every ~1250 bases.
![Page 4: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/4.jpg)
• Mutation: difference in the DNA code that occurs in less than 1% of population– Often associated with rare diseases
• Polymorphism: difference in the DNA code that occurs in more than 1% of the population– A single polymorphism is less likely to be
the main cause of a disease– Polymorphisms often have no visible clinical
impact
![Page 5: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/5.jpg)
Factors Contributing to Interindividual Variability in Drug Disposition and Action
• Age• Race/ethnicity• Weight• Gender• Concomitant Diseases• Concomitant Drugs• Social factors• GENETICS
![Page 6: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/6.jpg)
Factors that influence medication effects
• Absorption GIT P-glycoprotein• Drug metabolism phase-1 phase-2 reactions
![Page 7: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/7.jpg)
GIT- Antacids-> alter stomach pHdecreases
ketoconazole absorption.- GI transit time have a small role in drug
absorption variability. Anticholinergics slow down transit
times, crohn’s and ulcerative collitis can markedly increase transit times .
![Page 8: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/8.jpg)
drug Absorption site remarks
Ketoconazole GI tract Acidic environment improves absorption
cyclosporine PGP Affects bioavailability
Mycophenolete mofitel GI tract Not to be given with Fe(inhibits absorption)
![Page 9: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/9.jpg)
P-GLYCOPROTEIN• Is a membrane-bound transport protein affects
absorption in GIT. • Functions as a part of first pass effect by
actively pumping the drugs out from cell, there by decreasing bioavailability.
• High levels of PGP also found in liver and kidneys(drug elimination).
• Decreased intestinal P-gp function– increased amount absorbed– increased plasma concentration
![Page 10: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/10.jpg)
DRUG METABOLISM process that facilitates drug clearance by- Increasing solubility- Prodrugs to their active drugs form Can be divided into two components
a) phase -I : intra molecular modifications(reductases, oxidases, hydrolases)
-create a site for attachment of larger polar side chains (in P-II rxn)b) phase-II: results in conjugation of drug with an endogenous
substance by glucuronidase, sulphatase, acetylases, methylases.
Despite what the nomenclature suggests, there is no order in which these reactions take place.
![Page 11: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/11.jpg)
PHASE-I REACTIONS
![Page 12: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/12.jpg)
CYTOCHROME P-450 ENZYME SYSTEM OVERVIEW
• The cytochrome P-450 mono-oxygenase system (CYP-450) is largely responsible for catalysing phase1 reactions(70-80%).
• Complex supergene family: at least 40 enzymes expressed in human tissues.
• CYP1A2, 3A4, 2C9, 2C19, 2D6, 2E1 exert a major role in drug metabolism.
• Enzymes are located on smooth endoplasmic reticulum of most cells, but are found in variable concentrations.
• Hepatocytes have the greatest concentration of CYP enzymes.
ARE RESPONSIBLE FOR THE METABOLIC ELIMINATION OF MOST DRUGS CURRENTLY USED IN MEDICINE
![Page 13: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/13.jpg)
CYTOCHROME P-450 ENZYME SYSTEMNOMENCLATUREEg: CYP3A4• Classified by amino acid similarities
– 1ST No. family number– 2nd subfamily letter – Final number for each gene within the subfamily– asterisk followed by a number (and letter) for each
genetic (allelic) varianto allele *1 is the normal function gene (wild allele)o CYP2D6*1a gene encodes wild-type protein CYP2D6*1
![Page 14: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/14.jpg)
Drugs metabolized by various CYP isoforms
Isoform % of all drugs metabolism
CYP3A4 40-45%
CYP2D6 20-30%
CYP2C9 10%
CYP2C19 5%
CYP1A2 5%
![Page 15: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/15.jpg)
Polymorphisms –• Approximately 40% of human CYP-dependent drug
metabolism is carried out by polymorphic CYP enzymes.
• This polymorphism expressed as variable enzyme activity, thus effecting metabolism of drugs.
• Depending on enzyme activity, individuals designated as:
-poor metabolisers(PM) -Intermediate metabolisers(IM) -Extensive metabolisers(EM) -Ultrarapid metabolisers(URM)
![Page 16: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/16.jpg)
![Page 17: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/17.jpg)
![Page 18: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/18.jpg)
Importance- therapeutic index
![Page 19: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/19.jpg)
Drug induced- inhibition or induction of CYP isoforms
![Page 20: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/20.jpg)
CYP-3A4 VARIABILITY• Responsible for 40-50% of all phase-1 reactions
and accounts for up to 7% of GIT CYP activity.• Is co-expressed with P-glycoprotein in liver and
intestine.• Despite little genetic variability between
populations , there appears to be as much as 20 fold interindividual variability of enzyme activity.
• CYP-3A4*1B appears to be the most common variant allele decreased activity.
![Page 21: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/21.jpg)
![Page 22: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/22.jpg)
CYP-2D6 VARIABILITY• Shows significant pharmacological variation
and is integral in metabolism of numerous medications especially psychiatric and cardiac medications.
• almost 80 allelic variants.
• 20-30% drugs are metabolised through this pathway.
![Page 23: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/23.jpg)
CYP-2C9 polymorphisms• 10% drug metabolism.• Although there have been over 100 SNP
identified, only 2 variants have been shown to significantly reduce substrate affinity through inhibiting CYP activity.
• Homozygote CYP-2C9*3/*3, comprising 0.5% of populations , is considered to have marked clinical significance with very low CYP-2C6 activity.
![Page 24: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/24.jpg)
• CYP-2C9*3- role phenytoin induced cutaneous adverse drug reactions.
• Warfarin is the most clinically significant substrate.
• Fluconazole inhibition of CYP-2C9 can result in markedly elevated levels of warfarin.
![Page 25: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/25.jpg)
CYP2C19 • 5% of all drug
metabolism.
• PPI and numerous anticonvulsants are primarily substrates metabolized.
CYP1A2 polymorphism• Metabolize several
antipsychotic medications and theophylline.
• Environment and genetic factors are shown to influence the activity of CYP1A2.
• Inducers- Tobacco, OCP,
![Page 26: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/26.jpg)
Dihydropyrimidine dehydrogenase(DPD)• In metabolism of 5-FU.• More than 80% of given drug is metabolised by
DPD.• Deficiency of DPD have been reported to have
severe neurotoxicity from 5-FU treatment.• Severe gastrointestinal and hematological toxicity
reported with DPD deficient patient who applied it topically on scalp.
Therefore contraindicated in DPD deficient patients.
![Page 27: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/27.jpg)
Polymorphisms• Many genetic variants in DPD gene have been
described, most common DPD*2A allele, which leads to an enzymatically deficient DPD.
• This allele is associated with 5-FU induced toxicity specially leucopenia and mucositis.
![Page 28: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/28.jpg)
PHASE-2 REACTIONS
P-GLYCOPROTEIN(permeability glycoprotein)• Is an ATP-activated pump, increased attention
because of its role in multidrug resistance, in particular to chemotherapeutic agents.
• PGP involves pumping molecules from intracellular to extracellular spaces, countering the effects of passive diffusion, most notably in GIT, resultant decrease in net drug absorption.
![Page 29: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/29.jpg)
![Page 30: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/30.jpg)
Polymorphisms • Identified in the multidrug resistance1(MDR1)
gene that encodes PGP.
• This decreased expression is associated with increased drug concentrations(digoxin).
Importance-Significant overlap between PGP and CYP3A4,
limiting assessment of PGP polymorphisms.
![Page 31: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/31.jpg)
THIOPURINE METHYLTRANSFERASE(TPMT)
• Is a catalyst for the metabolism and inactivation of azathiopurine, 6-mercaptopurine(6-MP) and thioguanine.
• Function- converting 6-MP to active methyl mercaptopurine(6MMP) nucleotides and converting thioguanine to inactive metabolites.
• decreased activity results in increased 6-thioguanine levels, leading to increased toxicity(myelosuppression)
![Page 32: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/32.jpg)
6-MMP• is correlated with
azathiopurine-induced hepatoxicity.
• Decreased levels of formation in TPMT deficient individuals.
• Therefore, deficient individuals are at lower risk of developing hepatotoxicity.
![Page 33: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/33.jpg)
TPMT polymorphism• normal allele homozygous TPMT*1high
activity(89-90% popl’tn)
• Mutant alleles TPMT*3C, *3A *2 decreased activity
• Heterozygous expression along with TPMT*1 –results in intermediate TPMT activity(10-11%).
• Low to no TPMT activity0.3%{decreased hepatotoxicity & increased myelosuppression}
![Page 34: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/34.jpg)
Testing methods for TPMT polymorphisms • TPMT activity in erythrocytes• DNA micro-array studies
Clinical applicationi. TPMT*1(normal)– 2 to 2.5ml/kg/day
(standard dose)ii. Heterozygous with one mutant allele - dose
reduced by 15-50%.iii. Two mutant alleles – recommended that not to
be treated; if must, @ dose reduced by 90%.
![Page 35: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/35.jpg)
N-ACETYL TRANSFERASE (NAT2)• Acetylates numerous xenobiotics making the
parent compound water soluble, thus facilitating drug elimination.
• 25 allelic variants of NAT2 gene have been identified.
• Enzyme activity often reported as rapid, intermediate, or slow (analogous to EM,IM,PM).
![Page 36: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/36.jpg)
Rapid acetylators • homozygous for NAT2*4, NAT2*12 and NAT2*13.• Require higher doses of medications to minimize the
likelihood of treatment failure. Intermediate acetylators NAT2*5, *6, *7, *14Slow acetylators • More likely to develop toxic adverse effects, including drug induced lupus - procainamide and hydralazineneuropathy –isonaizdTEN – sulfonamides• Have increased risk certain solid tumors and for some
IgE-mediated food allergies seen in children
![Page 37: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/37.jpg)
GLUCOSE-6-PHOSPHATE DEHYDROGENASE • Catalyses the first reaction in the pentose
phosphate pathway(PPP), leading to reduction of NADP to NADPH.
• NADPH plays important role in reducing glutathione, which plays pivotal role preventing cell damage by oxidative stress.
• Since erythrocytes lack mitochondria, the PPP is the only source of NADPH, thus making erythrocytes sensitive to oxidative stress, resulting in hemolysis.
![Page 38: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/38.jpg)
![Page 39: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/39.jpg)
In a study of 3166 Indian’s, g6Pd deficiency is about 10.5%
![Page 40: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/40.jpg)
Glutathione S-transferase(GST)• Involved in detoxification of carcinogenic
derivatives of coal tar.• 50% Europeans have low to absent activity
owing to the presence of the GSTM1-null genotype.
• Hence , when these individuals are treated with topical coal tar have a greater mutagen exposure.
![Page 41: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/41.jpg)
Folate pathway polymorphisms• Methotrexate - structural analouge of folic acid which competitively
inhibits dihydrofolate reductase (DHFR).- Also directly inhibits thymidylate synthase(TS) - Influences the activity of methylene
tetrahydrofolate reductase(MTHFR), which converts homocysteine to methonine.
- The adverse drug reactions have been associated with polymorphisms of TS and MTHFR.
![Page 42: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/42.jpg)
• Thymidylate synthase (TS) 5’-untranslated region (TS 5’-UTR 3R)
- This allele has been significantly linked with ADR in psoriasis patients taking MTX when folic acid is not administered.
- associated with a poor therapeutic response to MTX.- Lower risk for 5-FU induced ADR.
• TS 5’-UTR 6 bp deletion allele has also been associated with increased MTX-induced toxicity , including up to an 8-fold increase of developing elevated ALT transaminase levels in absence of folic acid supplementation.
![Page 43: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/43.jpg)
• C677T polymorphism of MTHFR, observed in 8% of normal population, leads to a thermolabile variant subsequently reducing its activity to about 30% of wild type.
• This has been associated with an increased risk of discontinuing MTX because of elevation in liver enzymes.
![Page 44: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/44.jpg)
Severe cutaneous ADR and HLA associations
![Page 45: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/45.jpg)
• HLA-B*1502 & Carbamazepine (chinese)- Drug induced SJS and TEN- Not associated with hypersensitivity syndrome
• HLA-B*5801- Allopurinol induced severe cutaneous ADR.
• Abacavir hypersensitivity - HLA-B*5701(severe and fatal)- HLA-DQ3, HLA-DR7
![Page 46: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/46.jpg)
• Nevirapine (nnrti)- HLA-B*3505 is predictor for all types of
nevirapine induced cutaneous drug reactions(thai patients).
- HLA-DRB1*0101 hepatitis, fever, and rash, but not with isolated rash.
- ADR occur more frequently in patients with higher pre-treatment CD4 levels
- Therefore, it is now recommended that it should be avoided with CD4 count
women- >250/microL men- >400/microL
![Page 47: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/47.jpg)
Testsa) CYP2D6 polymorphisms- DNA microarray
analysisb) HLA polymorphisms- specific HLA typingc) TPMT-- phenotyping:- measures enzyme activity in
peripheral RBC lysates.- Genotyping:- DNA microarray, PCR,
prometheus TPMT genetics- genetic allele testing.
![Page 48: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/48.jpg)
d) G6PD• Fluorescent spot test- enzyme activity in
erythrocytes• Methemoglobin or nile blue sulfate reduction
G6PD studies• G6PD genotyping
e) Thymidylate synthase• Genotyping of 5’UTR repeats
f) GSTM1- PCR analysis
![Page 49: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/49.jpg)
• www.drug-interactions.com
![Page 50: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/50.jpg)
HEPATOTOXICITY OF DERMATOLOGIC DRUG THERAPY
![Page 51: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/51.jpg)
Drugs and liver injury
• Drugs are estimated to be responsible for 10% of cases of hepatitis in adults.
• 40-50% of hepatits in adults over 50yrs of age.• 25% of fulminant hepatitis.• Liver failure, when drug induced on an
idiosyncratic basis, is fatal 75-80% of the time.
![Page 52: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/52.jpg)
Hepatic drug metabolism- Major site of metabolism for most drugs- Overall goal of hepatic drug metabolism is to
convert pharmacologically active relatively lipophilic drugs into inactive relatively hydophilic metabolites(biotransformation) and conversion of reactive metabolic intermediates to more stable molecular compounds (detoxification).
- Reasonable balance between the two process keeps liver away from toxicity.
![Page 53: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/53.jpg)
Biotransformation• goal- lipophilic to hydrophilic• Increased hydrophilicity --> excreted by either
renal or billiary routes.
Detoxification• Goal- To avoid local or distant damage from
reactive intermediates(electrophilic compounds) during biotranformation.
These systems are adequate to allow safe drug administration without significant risk to liver.
![Page 54: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/54.jpg)
![Page 55: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/55.jpg)
Time period• Majority occur between 15-90 days after the initiation of
therapy.• Potentially serious hematologic drug reactions have a much
more gradual onset.
within 15 days after cessation- Marked improvement(mostly)- may lead to hepatocellular toxicity, hypersensitivity
syndrome and cholestasis type reactions.
Occurs over years- Steatosis progressing to fibrosis is much slower
![Page 56: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/56.jpg)
Outcome• Most are completely reversible if detected
early(days/ few weeks)• If detected relatively late, some are not fully
reversible.• Delayed diagnosis - Death- liver failure requiring transplantation- severe fibrosis or cirrhosis.
LOSS OF SOME DEGREE OF LIVER FUNCTION IS INDEFINITE
![Page 57: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/57.jpg)
Cellular and structural targets involved with DILD
Cell or structure Category of reaction Representative drug etiologies
Hepatocytes Hepatocellular necrosis
Ketoconazole, minocycline
Bile ducts, bile canaliculi
Cholestasis Erythromycin
Endothelial cells, sinusoids
Veno-occlusive Very high dose cyclophosphimide
Ito cells Steatosis-> fibrosis methotrexate
![Page 58: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/58.jpg)
Risk Factors For Susceptibility to DILD• Methotrexate
– Alcohol– Obesity– D.M– Chronic hepatitis– Renal insufficiency
• INH– HBV,HCV,HIV– Alcohol– Older age– Female
• Sulfonamide– HIV– Slow acetylator– Genetic defect in defense
• Anticonvulsants– Genetic defect in detoxification
• Acetaminophen– Alcohol– Fasting– INH
• Valproate– Young age– Anticonvulsants
• Diclofenac– Female– Osteoarthritis
• Rifampicin– Slow acetylators– INH
• Pyrazinamide– Slow acetylators– INH
![Page 59: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/59.jpg)
Drug specific risk factors• Daily dose- retinoid hepatotoxicity.• Cumulative dose- MTX induced liver disease.
Red flag signs in prescribing recently released medications
- Presence of significant number of patients in clinical trails with mild elevation in LFT.
- Report of even 1-2 deaths from drug hepatoxicity in clinical trails or very soon after drug’s release.
![Page 60: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/60.jpg)
Major classification systems in DILD 1) Based on laboratory test abnormalities(LFT)- hepatocellular:- elevated transaminases- Obstructive:- elevated ALP, GGT and bilirubin
values- Mixed:- combination of both (either type over
time commonly becomes ‘mixed’)2) Based liver histology- Steatosis(fatty liver)- Fibrosis to cirrhosis- Granulomatous- Veno-occlusive
![Page 61: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/61.jpg)
3) Based on pathogenesis - Toxic- Idiosyncratic a) metabolic- local toxic reactive
intermediates. b) immunologic- neoantigens
![Page 62: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/62.jpg)
Mechanisms of drug hepatoxicity
• Mainly by - Idiosyncratic(majority, unpredictable))- Toxic (dose dependent, predictable)
- Idiosyncratic DILD• Well accepted hypothesis:- Reactive
electrophilic intermediates with defective cellular detoxification systems
![Page 63: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/63.jpg)
![Page 64: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/64.jpg)
Metabolic targets involved with DILDmolecule consequence comments
Various proteins Neoantigen formation Reactive metabolites induce a change in structure or conformation
CYP proteins Neoantigen formation CYP especially vulnerable , due to proximity to reactive metabolites
DNA Apoptosis or necrosis results in cell death
Lipids Lose membrane integrity
Result of lipid peroxidation by reactive metabolites
![Page 65: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/65.jpg)
Hepatocellular Best diagnostic test
Classic culprit Dermatology drugs
Hepatocellular AST & ALT Halothane KetoconazoleDapsoneMinocyclineAzathioprineAcitretinMTX
Hypersensitivity AST, ALT & eosinophil count
Phenytion DapsoneMinocyclineAzathioprineSulfonamides
Cholestasis ALPGGTBilirubin(direct)
Chlorpromazine RifampinErythromycinTMP/SMX
Steatosisfibrosis Liver biopsyTransaminases
MTX Acetretin(rarely)
![Page 66: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/66.jpg)
Dapsone and azathioprineAll physicians will do careful hematologic
monitering, whereas far fewer will routinely check transaminase levels, another is the very ‘delayed’ discovery of the potential for minocycline to induce hepatotoxicity (an isolated findings) or DHS.
![Page 67: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/67.jpg)
Diagnostic algorithm1) Challenge- circumstances of the original drug course , drug
timing/reputation, patient history or prior reactions to the drug in question
2) Dechallenge- expected improvement after the drug is discontinued
3) Rechallenge- only when it is essential to know the responsible drug with certainty and the reaction pattern is a relatively low-risk adverse effect from drugs.
4) Exclusion- other non-drug etiologies for the same adverse effect.
‘Dechallenge’ and ‘exclusion’ steps are appropriate for virtually all patients with a 2-3 fold elevation of transaminase values.
![Page 68: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/68.jpg)
Transaminases1-2 fold elevation- - Reduce the drug dose and follow up the
transaminase values carefully.
Above 3- fold elevation(critical)-- Prompt indefinite discontinuation of the drug or
drugs likely to be responsible, unless an alternative etiology for this elevation is uncovered.
![Page 69: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/69.jpg)
• Hepatocyte integrity-- Specificity- ALT/SGPT>AST/SGOT - Greater sensitivity if both are ordered.
Periodic Liver biopsy- psoriasis patients on long term MTX therapy.
In rhematology, patients with RA and on MTX ; repeated elevations of transaminases i.e elevetions in 5 of 9 tests performed every 6 weeks, over a year or albumin levels <3 gm% are the published standard of care to indicate a need for a liver biopsy.
![Page 70: Polymorphisims why individual drug responses vary](https://reader035.fdocuments.us/reader035/viewer/2022062900/58ede57b1a28ab20298b46c3/html5/thumbnails/70.jpg)
Thank you